EDEN PRAIRIE, Minn., May 05, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that CFO Ron McClurg will present at the Sidoti Micro-Cap Virtual Conference being held May 10-11, 2023.
| Presentation date: | Wednesday, May 10, 2023 |
| Presentation time: | 10:45 a.m.* |
| Registration: | sidoti.com/events |
| Live presentation: | Session link |
| 1x1 meetings: | Investors may request meetings by contacting their Sidoti representative or NeuroOne Investor Relations. |
*Please note that the presentation date and time are subject to change. Attendees may refer to the program agenda for more information.
About NeuroOne
NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit nmtc1.com.
*Caution: Federal law restricts this device to sale by or on the order of a physician.
Contact:
800-631-4030
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.81 |
| Daily Change: | 0.02 2.04 |
| Daily Volume: | 94,291 |
| Market Cap: | US$40.450M |
August 18, 2025 July 23, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
